OBJECTIVES: The EQ-5D is a widely used generic preference-based measure (PBM) to derive Quality-Adjusted-Life-Years (QALYs) for use in economic evaluations. Such generic measures of health-related quality of life (HRQoL) could be insensitive for some medical conditions such as cancer. The European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire (EORTC QLQ-C30) is a widely used, non-PBM to assess the QoL in cancer patients. Although EORTC provides supplementary information for an economic evaluation, it does not produce a single QoL utility score such as that of the EQ-5D which can be used in economic analysis. Mapping is a technique to estimate the relationship between PBM (EQ-5D) and non-PBM (EORTC) to derive a single utility value. The objective of this study was to map the EORTC data from AC-01 trial onto the EQ-5D by identifying the most appropriate mapping algorithm in the literature. METHODS: A literature review of studies presenting an algorithm enabling utility values to be derived from EORTC data was conducted. The retrieved algorithms were compared in terms of study design, population, methodology, EORTC items/dimensions included in the final algorithm, and predictive performance. An EORTC-based utility value was calculated using the best algorithm identified. RESULTS: Algorithms were extracted from six sources. The algorithm reported by Rowen et al. (2011) was considered as the most appropriate when robustness of the methodology and the comprehensive nature of the dimensions compared. The EORTC-based mean utility scores calculated were 0.67 (SD= 0.13) and 0.64 (SD= 0.14) in the catumaxomab and control group at screening, respectively, and 0.72 (SD= 0.14) for the catumaxomab group at week 4.  CONCLUSIONS: The mapping algorithm developed by Rowen et al. (2011) enabled the whole possible range of patients’ health-status to be measured in the study. The derived utilities enable EORTC data to be used in economic evaluations.